Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

52-week follow-up data from type 1 diabetes (“T1D”) patients in COVALENT-112 who completed ≥80% of protocol-specified dosing with the read-out expected in the second quarter of 2026. 26-week primary ...

Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 ...

People who have type 2 diabetes have an increased amount of sugar in their blood, also called blood glucose. Increased blood sugar happens when your body’s insulin doesn’t work as well as it should.